natgillin/translations-raw huggingface dataset:
Fentanyl is excreted into human milk and may cause sedation/respiratory depression in a breastfed infant. 
Fentanil se izlučuje u majčino mlijeko te može izazvati sedaciju/depresiju disanja kod dojenčeta.
For management of respiratory depression, immediate countermeasures include removing the DUROGESIC patch and physically or verbally stimulating the patient. 
Protumjere koje se moraju odmah poduzeti za liječenje depresije disanja uključuju uklanjanje DUROGESIC flastera te fizičku ili verbalnu stimulaciju bolesnika.
Fentanyl concentrations were measured in more than 250 children aged 2 to 17 years who were applied fentanyl patches in the dose range of 12.5 to 300 mcg/h. 
Koncentracije fentanila određivale su se kod više od 250 djece u dobi od 2 do 17 godina kojima su primijenjeni flasteri s fentanilom u dozi od 12,5 do 300 µg/h.
• Tear or cut open the sachet at the notch, shown by the arrow 
• Otrgnite ili odrežite vrećicu na mjestu zareza duž ruba, na koji pokazuje strelica
There have been reports also of newborn infants experiencing withdrawal effects after their mothers have used DUROGESIC for a long time during pregnancy. 
Prijavljeni su slučajevi pojave simptoma ustezanja i kod novorođenčadi, nakon što su njihove majke koristile DUROGESIC dulje vrijeme tijekom trudnoće.
If you do, you may increase the amount of medicine you get from the patch. 
U protivnom možete povećati količinu lijeka koja se otpušta iz flastera.
Therefore, during the first 12 hours after switching to DUROGESIC, the patient should be given the previous regular dose of analgesics. 
Stoga tijekom prvih 12 sati nakon prelaska na DUROGESIC bolesniku treba nastaviti davati i dotadašnju uobičajenu dozu analgetika.
Dosage titration should normally be performed in 12 mcg/h or 25 mcg/h increments, although the supplementary analgesic requirements (oral morphine 45/90 mg/day ≈ DUROGESIC 12/25 mcg/h) and pain status of the patient should be taken into account. 
Doza se uobičajeno treba povećavati u koracima od 12 ili 25 µg/h, ali treba uzeti u obzir i dodatne potrebe za analgezijom (oralni morfin 45/90 mg/dan ≈ DUROGESIC 12/25 µg/h) te status boli kod bolesnika.
There are no adequate data from the use of DUROGESIC in pregnant women. 
Nema odgovarajućih podataka o primjeni lijeka DUROGESIC kod trudnica.
However, as the influence of renal impairment on the pharmacokinetics of fentanyl has not been evaluated, caution is advised (see sections 4.2 and 4.4). 
Međutim, kako se utjecaj oštećenja bubrežne funkcije na farmakokinetiku fentanila nije ocjenjivao, preporučuje se oprez (vidjeti dijelove 4.2 i 4.4)
DATE OF REVISION OF THE TEXT <{DD month YYYY}> [To be completed nationally] 
DATUM REVIZIJE TEKSTA <{DD mjesec GGGG}>
Patients with a prior history of drug dependence/alcohol abuse are more at risk to develop dependence and abuse in opioid treatment. 
Bolesnici koji su prethodno bili ovisni o lijekovima ili su prekomjerno uživali alkohol izloženi su većem riziku razvoja ovisnosti i zlouporabe tijekom liječenja opioidima.
Caution should be exercised when treating patients with myasthenia gravis. 
Potreban je oprez kada se liječe bolesnici s miastenijom gravis.
• DUROGESIC patches are for long-term pain. 
• DUROGESIC flasteri namijenjeni su za liječenje dugotrajne boli.
• Press this sticky part of the patch onto the skin 
• Pritisnite ljepljivi dio flastera na kožu
DUROGESIC may have more severe adverse effects in patients with chronic obstructive or other pulmonary disease. 
DUROGESIC može imati teže nuspojave kod bolesnika s kroničnom opstruktivnom ili drugom plućnom bolešću.
A lag time of 12 to 24 hours after application of the first patch and after a dose increase must be taken into account. 
Mora se uzeti u obzir vrijeme do nastupa punog učinka od 12 do 24 sata nakon prve primjene flastera i povećanja doze.
• Remove the other part of the backing and press the whole patch onto the skin with the palm of your hand 
• Uklonite drugu polovicu zaštitne folije i dlanom pritisnite cijeli flaster na kožu
• Medicines for helping you sleep (such as temazepam, zaleplon, or zolpidem). 
• lijekove koji Vam pomažu zaspati (npr. temazepam, zaleplon ili zolpidem)
To prevent overdose it is recommended that opioid-naïve patients receive low doses of immediate-release opioids (eg, morphine, hydromorphone, oxycodone, tramadol, and codeine) that are to be titrated until an analgesic dosage equivalent to DUROGESIC with a release rate of 12 mcg/h or 25 mcg/h is attained. 
Kako bi se spriječilo predoziranje, preporučuje se da bolesnici koji prethodno nisu primali opioide primaju male doze opioida s trenutnim oslobađanjem (npr. morfina, hidromorfona, oksikodona, tramadola i kodeina), koje treba titrirati dok se ne dosegne analgetska doza koja odgovara lijeku DUROGESIC s brzinom oslobađanja od 12 µg/h ili 25 µg/h.
The dose should be titrated individually on the basis of average daily use of supplemental analgesics, until a balance between analgesic efficacy and tolerability is attained. 
Dozu treba titrirati kod svakog bolesnika pojedinačno na temelju prosječne dnevne doze dodatnih analgetika dok se ne postigne ravnoteža između analgetske djelotvornosti i podnošljivosti.
Respiratory depression may persist beyond the removal of the DUROGESIC patch. 
Depresija disanja može potrajati i nakon uklanjanja DUROGESIC
Underlying, symptomatic hypotension and/or hypovolaemia should be corrected before treatment with fentanyl transdermal patches is initiated. 
Podležeću simptomatsku hipotenziju i/ili hipovolemiju treba korigirati prije početka liječenja transdermalnim flasterima s fentanilom.
• Constricted pupils (miosis) 
• sužene zjenice (mioza)
Extra caution should be used in patients with chronic constipation. 
Potreban je dodatan oprez kod bolesnika s kroničnom konstipacijom.
Caution is advised upon concomitant use of CYP3A4 inducers and DUROGESIC. 
Preporučuje se oprez pri istodobnoj primjeni induktora CYP3A4 i lijeka DUROGESIC.
The dose should be titrated individually until a balance between analgesic efficacy and tolerability is attained. 
Dozu treba titrirati kod svakog bolesnika pojedinačno dok se ne postigne ravnoteža između analgetske djelotvornosti i podnošljivosti.
• Heart beat feels fast or uneven (palpitations, tachycardia) 
• ubrzani ili neravnomjerni otkucaji srca (palpitacije, tahikardija)
The dose of DUROGESIC may need to be increased or a switch to another analgesic active substance may be needed. 
Možda će biti potrebno povećati dozu lijeka DUROGESIC ili prebaciti bolesnika na drugu analgetsku djelatnu tvar.
DUROGESIC may interact with these medicines and you may experience changes to mental status such as feeling agitated, seeing, feeling, hearing, or smelling things that are not there (hallucinations) and other effects such as changing blood pressure, fast heart beat, high body temperature, overactive reflexes, lack of coordination, muscle stiffness, nausea, vomitting and diarrhoea. 
DUROGESIC može imati djelovati na te lijekove i može doći do promjena psihičkog stanja kao što su uznemirenost, halucinacije (kada vidite, osjećate, čujete ili možete namirisati stvari koje nisu prisutne) i drugih učinaka poput promjena krvnog tlaka, ubrzanog rada srca, povišene tjelesne temperature, pojačanih refleksa, nedostatka koordinacije, ukočenosti mišića, mučnine, povraćanja i proljeva.
Examples of active substance that may decrease fentanyl plasma concentrations include: carbamazepine, phenobarbital, phenytoin and rifampicin (this list is not exhaustive). 
Primjeri djelatnih tvari koje mogu smanjiti koncentracije fentanila u plazmi uključuju: karbamazepin, fenobarbital, fenitoin i rifampicin (ovaj popis nije konačan).
Therefore, they must keep all patches out of the sight and reach of children, both before and after use. 
Stoga, sve flastere i prije i poslije primjene moraju čuvati izvan pogleda i dohvata djece.
It is recommended that DUROGESIC be used in patients who have demonstrated opioid tolerance. 
Preporučuje se koristiti DUROGESIC kod bolesnika koji su pokazali toleranciju na opioide.
DUROGESIC doses should be individualised based upon the status of the patient and should be assessed at regular intervals after application. 
Doze lijeka DUROGESIC treba odrediti za svakog bolesnika pojedinačno na temelju njegova statusa te ih nakon početka primjene treba redovito procjenjivati.
Of these 110 subjects, 23 (20.9%) had previously been receiving <30 mg of oral morphine equivalents per day, 66 (60.0%) had been receiving 30 to 44 mg of oral morphine equivalents per day, and 12 (10.9%) had been receiving at least 45 mg of oral morphine equivalents per day (data not available for 9 [8.2%] subjects). 
110 ispitanika, njih 23 (20,9%) prethodno je primalo dozu opioida ekvivalentnu < 30 mg oralnog morfina na dan, 66 (60,0%) ih je primalo dozu opioida ekvivalentnu 30 do 44 mg oralnog morfina na dan, dok je 12 ispitanika primalo dozu opioida ekvivalentnu najmanje 45 mg oralnog morfina na dan (nisu bili dostupni podaci za 9 [8,2%] ispitanika).
If serotonin syndrome is suspected, treatment with DUROGESIC should be discontinued. 
U slučaju sumnje na serotoninski sindrom, liječenje lijekom DUROGESIC mora se prekinuti.
Initial evaluation of the maximum analgesic effect of DUROGESIC cannot be made before the patch is worn for 24 hours. 
Početnu ocjenu maksimalnog analgetskog učinka lijeka DUROGESIC nije moguće provesti prije nego što se flaster nosi 24 sata.
Therefore, DUROGESIC should not be used within 14 days after discontinuation of treatment with MAOIs. 
Stoga se DUROGESIC ne smije primjenjivati unutar 14 dana nakon završetka liječenja MAO inhibitorima.
This is because fentanyl concentrations fall gradually after DUROGESIC is removed. 
To je potrebno zato što se koncentracije fentanila postupno smanjuju nakon odstranjenja lijeka DUROGESIC.
Skin temperature elevation may enhance the absorption of transdermally-applied fentanyl (see section 4.4). 
Porast temperature kože može pojačati apsorpciju transdermalno primijenjenog fentanila (vidjeti dio 4.4).
Pharmacokinetic-related interactions 
Interakcije povezane s farmakokinetikom
Data in subjects with cirrhosis and simulated data in subjects with different grades of impaired liver function treated with transdermal fentanyl suggest that fentanyl concentrations may be increased, and fentanyl clearance may be decreased compared to subjects with normal liver function. 
Podaci prikupljeni kod ispitanika s cirozom i simulirani podaci za ispitanike s različitim stupnjevima oštećenja jetrene funkcije liječene transdermalnim fentanilom ukazuju na to da koncentracije fentanila mogu biti povišene i da klirens fentanila može biti smanjen u usporedbi s ispitanicima s normalnom jetrenom funkcijom.
Other medicines and DUROGESIC 
Drugi lijekovi i DUROGESIC
Talk to your doctor or pharmacist before using this medicine if any of the following apply to youyour doctor may need to check you more closely if: 
Obratite se svom liječniku ili ljekarniku prije nego primijenite ovaj lijek ako se bilo što od navedenoga odnosi na Vas - liječnik će Vas možda morati pažljivije kontrolirati: • ako ste ikada imali tegobe s plućima ili disanjem
• As soon as you take a patch off, fold it firmly in half so that the sticky side sticks to itself 
• Odmah nakon što skinete flaster, presavinite ga čvrsto popola tako da ljepljive strane naliježu jedna na drugu
To guard against accidental ingestion by children, use caution when choosing the application site for DUROGESIC (see sections 4.2 and 6.6) and monitor adhesion of the patch closely. 
Kako bi se dijete zaštitilo od slučajnog gutanja flastera, potreban je oprez pri odabiru mjesta primjene lijeka DUROGESIC (vidjeti dijelove 4.2 i 6.6) i pažljivo praćenje prianjanja flastera.
DUROGESIC should not be used during pregnancy unless you have discussed this with your doctor. 
DUROGESIC se ne smije primjenjivati tijekom trudnoće ako o tome prethodno niste razgovarali sa svojim liječnikom.
In two paediatric studies, the required fentanyl transdermal patch dose was calculated conservatively: 30 mg to 44 mg oral morphine per day or its equivalent opioid dose was replaced by one DUROGESIC 12 mcg/h patch. 
U dva pedijatrijska ispitivanja, potrebna doza fentanila u transdermalnom flasteru preračunata je konzervativno: 30 mg do 44 mg oralnog morfina na dan ili ekvivalentna doza opioida zamijenjena je jednim DUROGESIC 12 µg/h flasterom.
There is a high inter-subject variability in fentanyl pharmacokinetics, in the relationships between fentanyl concentrations, therapeutic and adverse effects, and in opioid tolerance. 
Postoji velika interindividualna varijabilnost s obzirom na farmakokinetiku fentanila, odnose između koncentracija fentanila, terapijskih učinaka i nuspojava te toleranciju na opioide.
Patients who have experienced serious adverse events should be monitored for at least 24 hours after removal of DUROGESIC, or more, as clinical symptoms dictate, because serum fentanyl concentrations decline gradually and are reduced by about 50% 20 to 27 hours later. 
4.4 Posebna upozorenja i mjere opreza pri uporabi Bolesnike kod kojih su se javile ozbiljne nuspojave treba nadzirati tijekom najmanje 24 sata ili dulje nakon uklanjanja lijeka DUROGESIC, sukladno kliničkim simptomima, jer serumske koncentracije fentanila opadaju postupno i smanjuju se za približno 50% nakon 20 do 27 sati.
DUROGESIC should be used with caution in patients with brain tumours. 
DUROGESIC treba primjenjivati uz oprez kod bolesnika s moždanim tumorima.
The safety of DUROGESIC was evaluated in 289 paediatric subjects (<18 years) who participated in 3 clinical studies for the management of chronic or continuous pain of malignant or non-malignant origin. 
Pedijatrijska populacija Sigurnost lijeka DUROGESIC ocjenjivala se kod 289 pedijatrijskih ispitanika (< 18 godina) koji su sudjelovali u 3 klinička ispitivanja primjene za liječenje kronične ili neprekidne boli malignog ili nemalignog podrijetla.
Caution is advised when DUROGESIC is co-administered with medicinal products that affect the serotonergic neurotransmitter systems. 
Preporučuje se oprez pri istodobnoj primjeni lijeka DUROGESIC i drugih lijekova koji utječu na sustave serotoninergičkih neuroprijenosnika.
1 Conversion to DUROGESIC dosages greater than 25 mcg/h is the same for paediatric patients as it is for adult patients 
1 Preračunavanje za doze lijeka DUROGESIC veće od 25 µg/h jednako je za pedijatrijske bolesnike i za odrasle bolesnike (vidjeti Tablicu 2).
Central Nervous System conditions including increased intracranial pressure DUROGESIC should be used with caution in patients who may be particularly susceptible to the intracranial effects of CO2 retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. 
DUROGESIC treba primjenjivati uz oprez kod bolesnika koji bi mogli biti posebno osjetljivi na intrakranijalne učinke zadržavanja CO2, kao što su bolesnici s povišenim intrakranijalnim tlakom, poremećajima svijesti ili bolesnici u komi.
• Other medicines for pain, such as other opioid painkillers (such as buprenorphine, nalbuphine, or pentazocine). 
• druge lijekove za bol, kao što su drugi opioidni lijekovi protiv boli (npr. buprenorfin, nalbufin ili pentazocin)
Patients should be advised on measures to prevent constipation and prophylactic laxative use should be considered. 
Bolesnike treba upoznati s mjerama za sprječavanje konstipacije te treba razmotriti profilaktičku primjenu laksativa.
CYP3A4 Inhibitors 
Inhibitori CYP3A4
• Your upper body or arm 
• gornjem dijelu tijela ili nadlaktici
Cases of serious respiratory depression after coadministration of CYP3A4 inhibitors with transdermal fentanyl have been reported, including a fatal case after coadministration with a moderate CYP3A4 inhibitor. 
Prijavljeni su slučajevi ozbiljne depresije disanja nakon istodobne primjene inhibitora CYP3A4 i transdermalnog fentanila, uključujući smrtni slučaj nakon istodobne primjene s umjerenim inhibitorom CYP3A4.
DUROGESIC may be worn continuously for 72 hours. 
DUROGESIC se može nositi neprekidno tijekom 72 sata.
Following DUROGESIC application, the skin under the system absorbs fentanyl, and a depot of fentanyl concentrates in the upper skin layers. 
Nakon nanošenja lijeka DUROGESIC, koža ispod sustava apsorbira fentanil te se u gornjim slojevima kože stvara depo koncentrata fentanila.
The concomitant use of other central nervous system depressants, (including opioids, sedatives, hypnotics, general anaesthetics, phenothiazines, tranquilizers, sedating antihistamines, and alcoholic beverages) and skeletal muscle relaxants, may produce additive depressant effects; hypoventilation, hypotension, profound sedation, coma or death may occur. 
Lijekovi koji djeluju na središnji živčani sustav i alkohol Istodobna primjena drugih depresora središnjeg živčanog sustava (uključujući opioide, sedative, hipnotike, opće anestetike, fenotiazine, trankvilizatore, sedirajuće antihistaminike i alkoholna pića) i relaksansa skeletnih mišića može dovesti do aditivnih depresivnih učinaka; mogu nastupiti hipoventilacija, hipotenzija, duboka sedacija, koma ili smrt.
• Medicines to treat tuberculosis (such as rifampicin). 
• lijekove koji se koriste za liječenje tuberkuloze (npr. rifampicin)
The concomitant use of CYP3A4 inhibitors and DUROGESIC is not recommended, unless the patient is closely monitored (see section 4.4). 
Ne preporučuje se istodobna primjena inhibitora CYP3A4 i lijeka DUROGESIC, osim u slučajevima kada se bolesnika pažljivo nadzire (vidjeti dio 4.4).
If you switch from a different painkiller to DUROGESIC or if you suddenly stop using DUROGESIC, you may notice withdrawal effects such as sickness, feeling sick, diarrhoea, anxiety or shivering. 
Ako prijeđete s drugog lijeka protiv boli na DUROGESIC ili ako naglo prestanete primjenjivati DUROGESIC, možda ćete primijetiti simptome ustezanja kao što su povraćanje, mučnina, proljev, tjeskoba ili drhtanje.
The resultant prolongation in gastrointestinal transit time may be responsible for the constipating effect of fentanyl. 
Posljedica toga je produljenje vremena prolaska kroz probavni sustav, koje bi moglo biti odgovorno za konstipacijski učinak fentanila.
• The patches are waterproof 
• Flasteri su vodootporni
Contents of the pack and other information What DUROGESIC contains [To be completed nationally] 
Sadržaj pakiranja i druge informacije Što DUROGESIC sadrži
These actions can be followed by administration of a specific opioid antagonist such as naloxone. 
Nakon tih mjera može se primijeniti specifičan opioidni antagonist, kao što je nalokson.
Monitoring of the patient for adverse events, which may include hypoventilation, is recommended for at least 48 hours after initiation of DUROGESIC therapy or up-titration of the dose (see section 4.4). 
Zbog moguće pojave nuspojava, koje mogu uključivati hipoventilaciju, preporučuje se nadzirati bolesnike tijekom najmanje 48 sati nakon uvođenja liječenja lijekom DUROGESIC ili nakon povećanja doze (vidjeti dio 4.4).
Therefore, the concomitant use of DUROGESIC and CYP3A4 inhibitors is not recommended unless the benefits outweigh the increased risk of adverse effects. 
Stoga se ne preporučuje istodobna primjena lijeka DUROGESIC i inhibitora CYP3A4, osim u slučajevima kada koristi nadmašuju povećan rizik od nuspojava.
The displayed frequency categories use the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare 
Prikazane kategorije učestalosti definirane su na sljedeći način: vrlo često (≥ 1/10); često (≥ 1/100 i
Among the remaining 5 subjects with a starting dosage of at least 25 mcg/h whose prior opioid doses were <45 mg of oral morphine equivalents per day, 1 (0.6%) had previously been receiving <30 mg of oral morphine equivalents per day and 4 (2.2%) had been receiving 30 to 44 mg of oral morphine equivalents per day (see section 4.8). 
Među preostalih 5 ispitanika s početnom dozom od najmanje 25 µg/h koji su prethodno primali doze opioida ekvivalentne < 45 mg oralnog morfina na dan, 1 (0,6%) je ispitanik prethodno primao dozu opioida ekvivalentnu < 30 mg oralnog morfina na dan, dok su njih 4 (2,2%) primala dozu opioida ekvivalentnu 30 do 44 mg oralnog morfina na dan (vidjeti dio 4.8).
Patches that are cut, divided, or damaged in any way should not be used. 
raspolovljeni ili oštećeni na bilo koji način.
The effects of the inducer decline gradually and may result in increased fentanyl plasma concentrations, which could increase or prolong both the therapeutic and adverse effects, and may cause serious respiratory depression. 
Učinci induktora smanjuju se postupno te mogu dovesti do porasta koncentracija fentanila u plazmi, što može pojačati ili produljiti i terapijske učinke i nuspojave te uzrokovati ozbiljnu depresiju disanja.
DUROGESIC can affect your ability to drive and use machines or tools as it may make you sleepy or dizzy. 
DUROGESIC može utjecati na Vašu sposobnost upravljanja vozilima i rada s alatima jer može izazvati pospanost ili omaglicu.
Very rarely these breathing difficulties can be life-threatening or even fatal, especially in people who have not used strong opioid painkillers (like DUROGESIC or morphine) before. 
Vrlo rijetko te dišne tegobe mogu biti opasne po život ili čak imati smrtni ishod, osobito kod ljudi koji prije nisu uzimali jake opioidne lijekove protiv bolova (poput lijeka DUROGESIC ili morfina).
If paralytic ileus is present or suspected, treatment with DUROGESIC should be stopped. 
U slučaju prisutnosti ili sumnje na paralitički ileus, liječenje lijekom DUROGESIC mora se prekinuti.
By the end of the second 72-hour application, a steady-state serum concentration is reached and is maintained during subsequent applications of a patch of the same size. 
Do kraja druge 72-satne primjene, koncentracija u serumu postiže stanje dinamičke ravnoteže, koje se održava daljnjom primjenom flastera iste veličine.
The serum fentanyl concentrations attained are proportional to the DUROGESIC patch size. 
Postignute koncentracije fentanila u serumu razmjerne su veličini DUROGESIC flastera.
The potential for serious or life-threatening hypoventilation exists regardless of the dose of DUROGESIC transdermal system administered. 
Mogućnost nastupa ozbiljne ili po život opasne hipoventilacije postoji neovisno o primijenjenoj dozi DUROGESIC transdermalnog flastera.
• Some medicines used to treat epilepsy (such as carbamazepine, phenobarbital, or phenytoin). 
• neke lijekove koji se koriste za liječenje epilepsije (npr. karbamazepin, fenobarbital ili fenitoin)
Starting dosages of 25 mcg/h and higher were used by the remaining 179 subjects, 174 (97.2%) of whom had been on opioid doses of at least 45 mg of oral morphine equivalents per day. 
Kod preostalih 179 ispitanika primjenjivale su se početne doze od 25 µg/h i više; 174 (97,2%) od tih ispitanika prethodno su primala doze opioida ekvivalentne najmanje 45 mg oralnog morfina na dan.
Dose adjustments should be done in 12 mcg/h steps. 
Dozu treba prilagođavati u koracima od 12 µg/h.
• Being unable to pass urine or empty bladder completely 
• nemogućnost mokrenja ili nepotpuno pražnjenje mjehura
Stopping suddenly may make you feel unwell 
Ako iznenadno prestanete primjenjivati flastere, možete se osjećati loše
Dose titration and maintenance therapy The DUROGESIC patch should be replaced every 72 hours. 
Titracija doze i terapija održavanja DUROGESIC flaster mora se mijenjati svaka 72 sata.
nausea (35.7%), vomiting (23.2%), constipation (23.1%), somnolence (15.0%), dizziness (13.1%), and headache (11.8%). 
somnolencija (15,0%), omaglica (13,1%) i glavobolja (11,8%).
Generally, the transdermal route is not recommended in opioid-naïve patients. 
Načelno se transdermalni put primjene ne preporučuje kod bolesnika koji prethodno nisu primali opioide.
DUROGESIC is for transdermal use. 
DUROGESIC je namijenjen za transdermalnu primjenu.
Cardiac disease 
Srčana bolest
Used patches should be folded firmly in half so that the sticky side of the patch sticks to itself. 
Upotrebljeni flasteri moraju se čvrsto presavinuti popola i to tako da ljepljiva strana naliježe sama na sebe.